ArticleOncoimmunology2020
Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study.
Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Article
- Comprehensive bioinformatics analysis of co-mutation ofTranslational cancer research · 2025Article
- Research trends and hotspots in the tumor microenvironment of ovarian cancer: a bibliometrics and visualization study from 2005 to 2024.Frontiers in immunology · 2025Article
- Identification of the key immune gene NR3C1 as a diagnostic biomarker in differentiating ovarian borderline tumors from benign tumors.Frontiers in cell and developmental biology · 2025Article
- Topology entropy: Enhancing graph partitioning for TAD identification and single-cell clustering.Computational and structural biotechnology journal · 2025Article
- Article
- Unlocking ovarian cancer heterogeneity: advancing immunotherapy through single-cell transcriptomics.Frontiers in oncology · 2024Review
- T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy.NPJ genomic medicine · 2023Article
- Incorporating cell hierarchy to decipher the functional diversity of single cells.Nucleic acids research · 2023Article
- TIMEDB: tumor immune micro-environment cell composition database with automatic analysis and interactive visualization.Nucleic acids research · 2023Article
- Identification of key immune genes of osteoporosis based on bioinformatics and machine learning.Frontiers in endocrinology · 2023Article
- Targeting the immune microenvironment for ovarian cancer therapy.Frontiers in immunology · 2023Review
- Review
- The STING pathway: Therapeutic vulnerabilities in ovarian cancer.British journal of cancer · 2022Review
- Identification of CD8Frontiers in genetics · 2022Article
- Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.Oncoimmunology · 2022Article
- RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.Frontiers in pharmacology · 2022Article
- Identification of Novel Hypoxia Subtypes for Prognosis Based on Machine Learning Algorithms.Journal of oncology · 2022Article
- Up-Frameshift Suppressor 3 as a prognostic biomarker and correlated with immune infiltrates: A pan-cancer analysis.PloS one · 2022Article
- Immune Subtypes Characterization Identifies Clinical Prognosis, Tumor Microenvironment Infiltration, and Immune Response in Ovarian Cancer.Frontiers in molecular biosciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of ovarian cancer (OC) remains the biggest challenge among gynecological malignancies. Immune checkpoint blockade therapy is promising in many cancers but shows low response rates in OC because of its heterogeneity. Although the biological and molecular heterogeneity of OC has been extensively investigated, heterogeneity of immune microenvironment remains elusive. We have collected the expression profiles of 3071 OC patients from 22 publicly available datasets. CIBERSORT was applied to infer the infiltration fraction of 22 immune cells among 2086 patients with CIBERSORT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.